• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏瓣膜病患者的心血管危险因素:一项全国性观察性队列研究。

Cardiovascular Risk Factors in Patients with Valvular Heart Disease: A Nationwide Observational Cohort Study.

作者信息

Lu Qianhong, Lv Junxing, Li Zhe, Ye Yunqing, Zhang Bin, Wang Weiwei, Zhao Qinghao, Zhang Haitong, Zhao Zhenyan, Wang Bincheng, Liu Qingrong, Yu Zikai, Duan Zhenya, Guo Shuai, Zhao Yanyan, Gao Runlin, Xu Haiyan, Wu Yongjian

机构信息

Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People's Republic of China.

Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100037, People's Republic of China.

出版信息

Int J Gen Med. 2024 Nov 28;17:5651-5664. doi: 10.2147/IJGM.S498982. eCollection 2024.

DOI:10.2147/IJGM.S498982
PMID:39624612
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11610399/
Abstract

PURPOSE

Conventional cardiovascular risk factors may contribute to the development of valvular heart disease (VHD). The present study sought to investigate the distribution of conventional modifiable cardiovascular risk factors (smoking, hypertension, hyperlipidemia, and diabetes) in various VHDs, the impact of risk factors on outcomes, and the prognostic indicators in patients with distinct burdens of risk factors.

PATIENTS AND METHODS

The study included 11862 patients with moderate or greater VHD. The primary outcome was a composite of all-cause mortality, hospitalization for heart failure, and myocardial infarction within two years.

RESULTS

Of 11862 patients with VHD, the mean age was 61.77 ± 13.51 years, and 44.4% were female. The prevalences of smoking, hypertension, hyperlipidemia, and diabetes were 14.9%, 45.0%, 13.4%, and 14.5% in the total cohort. Patients with zero, one, two, three, or four risk factors accounted for 39.4%, 38.2%, 17.7%, 4.3%, and 0.3%, respectively. The number of conventional risk factors was independently associated with two-year outcome in patients with mitral regurgitation (MR; three/four vs zero: hazard ratio [HR, 95% confidence interval (CI)]: 1.600 [1.106-2.315], P = 0.013; two vs zero: HR [95% CI]: 1.153 [0.867-1.532], P = 0.328; one vs zero: HR [95% CI]: 0.892 [0.687-1.159], P = 0.393). Stratified by the etiology of mitral valve lesions, each one risk factor increase was independently related to a 17.3% higher risk of adverse events in secondary MR. In patients with three or four risk factors, females had a significantly poorer outcome than males (P = 0.002).

CONCLUSION

More than one of five VHD patients had at least two conventional cardiovascular risk factors. The increasing number of risk factors indicated poor prognosis in patients with significant MR. Optimizing risk factor control may improve secondary prevention as well as long-term outcomes of VHD.

摘要

目的

传统心血管危险因素可能促成心脏瓣膜病(VHD)的发生。本研究旨在调查各种心脏瓣膜病中传统可改变心血管危险因素(吸烟、高血压、高脂血症和糖尿病)的分布情况、危险因素对结局的影响以及不同危险因素负担患者的预后指标。

患者与方法

本研究纳入了11862例中度及以上心脏瓣膜病患者。主要结局为两年内全因死亡率、因心力衰竭住院和心肌梗死的复合结局。

结果

在11862例心脏瓣膜病患者中,平均年龄为61.77±13.51岁,44.4%为女性。在整个队列中,吸烟、高血压、高脂血症和糖尿病的患病率分别为14.9%、45.0%、13.4%和14.5%。无、一、二、三或四个危险因素的患者分别占39.4%、38.2%、17.7%、4.3%和0.3%。在二尖瓣反流(MR)患者中,传统危险因素的数量与两年结局独立相关(三/四个危险因素与无危险因素相比:风险比[HR,95%置信区间(CI)]:1.600[1.106 - 2.315],P = 0.013;两个危险因素与无危险因素相比:HR[95%CI]:1.153[0.867 - 1.532],P = 0.328;一个危险因素与无危险因素相比:HR[95%CI]:0.892[0.687 - 1.159],P = 0.393)。按二尖瓣病变病因分层,在继发性二尖瓣反流中,每增加一个危险因素,不良事件风险独立增加17.3%。在有三个或四个危险因素的患者中,女性的结局明显比男性差(P = 0.002)。

结论

五分之一以上的心脏瓣膜病患者至少有两种传统心血管危险因素。危险因素数量增加表明重度二尖瓣反流患者预后不良。优化危险因素控制可能改善心脏瓣膜病的二级预防以及长期结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eee/11610399/ef11992b546c/IJGM-17-5651-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eee/11610399/83d76b00900d/IJGM-17-5651-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eee/11610399/ef11992b546c/IJGM-17-5651-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eee/11610399/83d76b00900d/IJGM-17-5651-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1eee/11610399/ef11992b546c/IJGM-17-5651-g0002.jpg

相似文献

1
Cardiovascular Risk Factors in Patients with Valvular Heart Disease: A Nationwide Observational Cohort Study.心脏瓣膜病患者的心血管危险因素:一项全国性观察性队列研究。
Int J Gen Med. 2024 Nov 28;17:5651-5664. doi: 10.2147/IJGM.S498982. eCollection 2024.
2
Sex Differences in Cardiovascular-Kidney-Metabolic Risk Factors Associated with Degenerative Valvular Heart Disease.与退行性心脏瓣膜病相关的心血管-肾脏-代谢危险因素的性别差异
Eur J Prev Cardiol. 2025 Feb 12. doi: 10.1093/eurjpc/zwaf050.
3
Meta-Analysis Global Group in Chronic Heart Failure score for the prediction of mortality in valvular heart disease.Meta 分析全球慢性心力衰竭组评分对瓣膜性心脏病患者死亡率的预测。
ESC Heart Fail. 2024 Feb;11(1):349-365. doi: 10.1002/ehf2.14586. Epub 2023 Nov 27.
4
Prevalence and impact of diabetes in patients with valvular heart disease.瓣膜性心脏病患者中糖尿病的患病率及影响
iScience. 2024 Feb 1;27(3):109084. doi: 10.1016/j.isci.2024.109084. eCollection 2024 Mar 15.
5
Clinical Impact of Valvular Heart Disease in Elderly Patients Admitted for Acute Coronary Syndrome: Insights From the Elderly-ACS 2 Study.老年急性冠状动脉综合征患者瓣膜性心脏病的临床影响:老年急性冠状动脉综合征 2 研究的新发现。
Can J Cardiol. 2020 Jul;36(7):1104-1111. doi: 10.1016/j.cjca.2019.11.014. Epub 2019 Nov 21.
6
Relationship between valvular structure and biochemical indices of non-valvular atrial fibrillation and senile degenerative valvular heart disease.非瓣膜性心房颤动与老年退行性心脏瓣膜病的瓣膜结构与生化指标之间的关系
J Thorac Dis. 2023 Feb 28;15(2):611-619. doi: 10.21037/jtd-23-61. Epub 2023 Feb 23.
7
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide in Elderly Patients With Valvular Heart Disease.N 端脑利钠肽前体在老年瓣膜性心脏病患者中的预后价值。
J Am Coll Cardiol. 2020 Apr 14;75(14):1659-1672. doi: 10.1016/j.jacc.2020.02.031.
8
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.ENGAGE AF-TIMI 48 试验中服用依度沙班或华法林的瓣膜性心脏病患者。
J Am Coll Cardiol. 2017 Mar 21;69(11):1372-1382. doi: 10.1016/j.jacc.2016.12.031.
9
Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey.多瓣膜心脏疾病患者的特征、治疗和结局:EURObservational Research Programme Valvular Heart Disease II 调查的一项子研究。
Eur Heart J. 2022 Aug 1;43(29):2756-2766. doi: 10.1093/eurheartj/ehac209.
10
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation.非瓣膜性心房颤动患者瓣膜性心脏病的预后意义。
BMC Cardiovasc Disord. 2021 Sep 18;21(1):453. doi: 10.1186/s12872-021-02264-3.

引用本文的文献

1
Gender specific echocardiographic prevalence of valvular stenosis and regurgitations in a large inpatient database of 24,265 patients.在一个包含24265名患者的大型住院患者数据库中,瓣膜狭窄和反流的性别特异性超声心动图患病率。
Am J Cardiovasc Dis. 2025 Feb 15;15(1):21-28. doi: 10.62347/HYOC9461. eCollection 2025.

本文引用的文献

1
Prevalence and impact of diabetes in patients with valvular heart disease.瓣膜性心脏病患者中糖尿病的患病率及影响
iScience. 2024 Feb 1;27(3):109084. doi: 10.1016/j.isci.2024.109084. eCollection 2024 Mar 15.
2
Cardiology's new crystal ball: machine learning for outcome prediction.
Eur Heart J. 2024 Feb 21;45(8):610-612. doi: 10.1093/eurheartj/ehad847.
3
Meta-Analysis Global Group in Chronic Heart Failure score for the prediction of mortality in valvular heart disease.Meta 分析全球慢性心力衰竭组评分对瓣膜性心脏病患者死亡率的预测。
ESC Heart Fail. 2024 Feb;11(1):349-365. doi: 10.1002/ehf2.14586. Epub 2023 Nov 27.
4
Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.经导管主动脉瓣置换术在五年内的低危患者中的应用。
N Engl J Med. 2023 Nov 23;389(21):1949-1960. doi: 10.1056/NEJMoa2307447. Epub 2023 Oct 24.
5
Uric Acid Levels, Number of Standard Modifiable Cardiovascular Risk Factors, and Prognosis in Patients With Coronary Artery Disease: A Large Cohort Study in Asia.尿酸水平、标准可调节心血管风险因素数量与冠心病患者预后的关系:亚洲一项大型队列研究。
J Am Heart Assoc. 2023 Oct 17;12(20):e030625. doi: 10.1161/JAHA.123.030625. Epub 2023 Oct 7.
6
Diabetes Mellitus in Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair-A Decade Experience in 1000+ Patients.接受二尖瓣经导管缘对缘修复术患者的糖尿病——1000 多名患者的十年经验
J Clin Med. 2023 May 16;12(10):3502. doi: 10.3390/jcm12103502.
7
Cardiovascular Risk Factor Control in 70- to 95-Year-Old Individuals: Cross-Sectional Results from the Population-Based AugUR Study.70至95岁人群心血管危险因素的控制:基于人群的AugUR研究的横断面结果
J Clin Med. 2023 Mar 7;12(6):2102. doi: 10.3390/jcm12062102.
8
Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation.经导管修复二尖瓣反流后的 5 年随访。
N Engl J Med. 2023 Jun 1;388(22):2037-2048. doi: 10.1056/NEJMoa2300213. Epub 2023 Mar 5.
9
Transcatheter Repair for Patients with Tricuspid Regurgitation.经导管三尖瓣反流修复术治疗患者。
N Engl J Med. 2023 May 18;388(20):1833-1842. doi: 10.1056/NEJMoa2300525. Epub 2023 Mar 4.
10
Distribution, Characteristics, and Management of Older Patients With Valvular Heart Disease in China: China-DVD Study.中国老年心脏瓣膜病患者的分布、特征及管理:中国心脏瓣膜病注册登记研究
JACC Asia. 2022 Apr 12;2(3):354-365. doi: 10.1016/j.jacasi.2021.11.013. eCollection 2022 Jun.